Wall Street Zen upgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning.

Other analysts also recently issued reports about the stock. Raymond James Financial reissued a “strong-buy” rating and issued a $165.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Morgan Stanley set a $137.00 price objective on Mirum Pharmaceuticals in a report on Thursday. Citizens Jmp dropped their target price on Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a report on Thursday. Evercore reaffirmed an “outperform” rating and issued a $138.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, May 7th. Finally, Royal Bank Of Canada dropped their price objective on Mirum Pharmaceuticals from $148.00 to $135.00 and set an “outperform” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $137.33.

Read Our Latest Analysis on MIRM

Shares of MIRM opened at $100.65 on Friday. Mirum Pharmaceuticals has a 1 year low of $57.79 and a 1 year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.86 and a quick ratio of 1.99. The stock has a 50 day simple moving average of $110.33 and a two-hundred day simple moving average of $101.79. The firm has a market cap of $6.14 billion, a P/E ratio of -6.92 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to analysts’ expectations of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company’s revenue was up 37.9% compared to the same quarter last year. During the same period last year, the business posted ($0.12) earnings per share. On average, analysts forecast that Mirum Pharmaceuticals will post -4.42 earnings per share for the current fiscal year.

In other news, CFO Eric Bjerkholt sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $122.25, for a total transaction of $611,250.00. Following the transaction, the chief financial officer directly owned 42,181 shares of the company’s stock, valued at approximately $5,156,627.25. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $95.84, for a total value of $2,875,200.00. Following the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at approximately $18,622,574.56. This represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 67,155 shares of company stock worth $7,185,662 in the last 90 days. Company insiders own 8.32% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in MIRM. Comerica Bank raised its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock worth $40,000 after purchasing an additional 278 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Mirum Pharmaceuticals by 307.3% during the 1st quarter. AQR Capital Management LLC now owns 49,076 shares of the company’s stock valued at $2,211,000 after purchasing an additional 37,028 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Mirum Pharmaceuticals by 7.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,047 shares of the company’s stock valued at $1,176,000 after buying an additional 1,720 shares during the period. Caxton Associates LLP bought a new stake in Mirum Pharmaceuticals during the 1st quarter valued at approximately $217,000. Finally, Empowered Funds LLC boosted its position in Mirum Pharmaceuticals by 15.4% during the 1st quarter. Empowered Funds LLC now owns 38,386 shares of the company’s stock valued at $1,729,000 after acquiring an additional 5,120 shares in the last quarter.

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue reached $176.24 million, beating the $166.33 million consensus estimate and rising 37.9% year over year. Growth was driven by Livmarli and Mirum’s other bile-acid therapies. Management also raised its 2026 sales outlook, providing a favorable signal about demand and the company’s commercial trajectory. Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts remain broadly constructive despite reducing their targets. TD Cowen lowered its target to $140 and retained a “buy” rating; Citizens JMP cut its target to $137 but maintained “market outperform”; and HC Wainwright reduced its target to $140 while keeping a “buy” rating. These targets imply substantial potential upside from recent trading levels.
• Neutral Sentiment: Mirum reported a quarterly loss of $1.06 per share, wider than the $0.74 consensus loss and the $0.12 loss recorded a year earlier. The loss reflects continued investment in the company’s rare-disease pipeline, but it remains a near-term valuation concern. Mirum’s Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
• Negative Sentiment: Citizens warned that an “unexpected” FDA request for a Phase 3 study clouds Mirum’s near-term outlook. The additional regulatory requirement could delay development or approval plans, increase spending, and weigh on investor sentiment.
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734, reducing her direct holdings by 59.1%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its signaling value, but the sale still adds a modest negative headline.

(Get Free Report)

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

• Five stocks we like better than Mirum Pharmaceuticals
• Quantum Earnings Week: Winners and Losers Are Finally Emerging
• Axon’s Post-Earnings Pullback May Be More About Valuation Than Growth
• Uber Stock Lags in 2026, But Cash Flow and AV Bets Fuel Upside
• AppLovin Stock Hits 52-Week Low as Analysts Trim Targets, Stay Bullish

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Chesley Taft & Associates LLC Reduces Position in Adobe Inc. $ADBE

Veeco Instruments (NASDAQ:VECO) Upgraded by Wall Street Zen to “Buy” Rating